This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cao, Y. Articles by Junck, L. Search for Related Content PubMed PubMed Citation Articles by Cao, Y. Articles by Junck, L. Social Bookmarking                            What's this?

Physiologic and Metabolic Magnetic Resonance Imaging in Gliomas

From the Departments of Radiation Oncology, Radiology, and Neurology, University of Michigan, Ann Arbor, MI

Address reprint requests to Yue Cao, PhD, Department of Radiation Oncology, University of Michigan, 1500 E Medical Center Dr, UH-B2C431, Box 0010, Ann Arbor, MI 48109-0010; e-mail: yuecao{at}umich.edu

Magnetic resonance (MR) imaging provides excellent soft tissue differentiation and in vivo assessment of physiologic and metabolic properties of tissue. As new and more aggressive treatment modalities and combined modalities are being investigated for brain tumor treatment, it is becoming more important to accurately define tumor volumes for treatment planning, to determine the most aggressive tumor regions for intensified radiation treatment, to identify early regional response to therapy for reoptimization of treatment, and to detect early indicators of developing normal tissue toxicity. Readily available MR techniques of physiologic and metabolic imaging can currently provide useful information regarding tumor tissue properties including chemical composition, cerebral blood volume, perfusion, vascular permeability, and water mobility. This article will focus on the potential value of MR physiologic and metabolic imaging in the clinical management of malignant gliomas.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. A. Brandes, A. Tosoni, F. Spagnolli, G. Frezza, M. Leonardi, F. Calbucci, and E. Franceschi Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology Neuro-oncol, January 1, 2008; 10(3): 361 - 367. [Abstract] [Full Text] [PDF]

				Q. Zhou, P. Guo, G. D. Kruh, P. Vicini, X. Wang, and J. M. Gallo Predicting Human Tumor Drug Concentrations from a Preclinical Pharmacokinetic Model of Temozolomide Brain Disposition Clin. Cancer Res., July 15, 2007; 13(14): 4271 - 4279. [Abstract] [Full Text] [PDF]

				N. U. Lin and E. P. Winer Brain Metastases: The HER2 Paradigm Clin. Cancer Res., March 15, 2007; 13(6): 1648 - 1655. [Abstract] [Full Text] [PDF]

				V. M. Savage, A. P. Allen, J. H. Brown, J. F. Gillooly, A. B. Herman, W. H. Woodruff, and G. B. West Scaling of number, size, and metabolic rate of cells with body size in mammals PNAS, March 13, 2007; 104(11): 4718 - 4723. [Abstract] [Full Text] [PDF]

				T. S. Lawrence, J. C. Buckner, and F. F. Lang CNS Malignancies: At Last, Real Progress J. Clin. Oncol., March 10, 2006; 24(8): 1225 - 1227. [Full Text] [PDF]